Pfizer Deal Marks A Missed Chance For Branded-Drug Cos.

Law360, New York (March 11, 2013, 8:37 PM EDT) -- By settling a Tenth Circuit challenge to its victory in an antidepressant suicide-warning case Friday, Pfizer Inc. may have forfeited the pharmaceutical industry's best shot at advancing the finding that federal law preempts some failure-to-warn claims over brand-name drugs, attorneys say.

The appeal centered on an Oklahoma federal judge's 2011 rejection of claims that Pfizer unit Wyeth Pharmaceuticals failed to warn an Effexor user of the risk of suicide linked to the antidepressant. The judge found there was clear evidence that the U.S. Food and Drug...
To view the full article, register now.